Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

The early metabolic stages in the evolution of antimicrobial resistance

Project description

Metabolic mechanisms of antimicrobial resistance

Antimicrobial resistance (AMR) is a growing global health problem, projected to cause millions of deaths and enormous economic losses by 2050. While much is known about genetic resistance, less is understood about pre-resistant bacterial cells that survive lethal antibiotic doses and pave the way for resistance. With the support of the Marie Skłodowska-Curie Actions programme, the MetEvoAMR project will study how metabolic adaptations help subpopulations of Pseudomonas aeruginosa and Acinetobacter baumannii transiently survive treatment. The research team will identify key metabolic and signalling pathways that support survival under antimicrobial stress. Findings are slated to reveal new targets that can be used to combat AMR and help design strategies to prevent the emergence of resistant bacteria.

Objective

Antimicrobial resistance (AMR) is a rising global health threat and rapid evolution of resistance against existing or newly developed antibacterial compounds is predicted to lead to 10 million deaths and $60 trillion of lost economic output by 2050. While resistance-conferring mutations, their inheritance and spread by horizontal gene transfer are increasingly well-studied, our understanding of “pre-resistant” cells’ survival and resilience in the presence of lethal antibacterial doses remains unclear. This proposal is stimulated by recent findings suggesting that the extracellular metabolic environment and metabolic adaptations play an overlooked role in transiently buffering antibiotic lethality and, therefore, increase the emergence of subpopulations of cells and their effective size that supports the evolution of antimicrobial resistance. In this proposal, I will systematically dissect mechanisms at work in subpopulations of “pre-resistant” cells of priority pathogens Pseudomonas aeruginosa and Acinetobacter baumannii that can transiently cope with antimicrobial treatment. I propose to combine my expertise in bacterial physiology with the Ralser Lab’s ultra-fast, massive-scale proteomics and phenomics technologies. I will systematically investigate the metabolic stress response in clinically relevant conditions, and identify the key metabolic and signalling processes that support the survival of subsets of challenged cells upon exposure to major classes of clinically applied antimicrobials. Finally, adaptive evolution experiments combined with CRISPR/Cas9 gene editing will validate causal effectors of identified tolerance mechanisms that precede the appearance of resistance-conveying adaptations. Here, I will acquire technical skills in innovative technologies and the host lab will benefit from my experience in working with pathogenic bacteria. I will lead public engagement efforts and disseminate scientific research outputs on an important global health issue.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2021-PF-01

See all projects funded under this call

Coordinator

CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Net EU contribution
€ 179 373,76
Address
Chariteplatz 1
10117 Berlin
Germany
Region
Berlin Berlin Berlin
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data